Chiral Supraparticles for Controllable Nanomedicine.
Biocompatible Materials
/ chemistry
Biosensing Techniques
/ methods
Cell Line
Cell Survival
/ drug effects
Cysteine
/ chemistry
Half-Life
Humans
Lipid Bilayers
/ metabolism
Lipids
/ chemistry
Microscopy, Confocal
Nanomedicine
Polyethylene Glycols
/ chemistry
Quartz Crystal Microbalance Techniques
Stereoisomerism
Thermodynamics
chirality
drug delivery systems
nanomedicine
self-assembly
supraparticles
Journal
Advanced materials (Deerfield Beach, Fla.)
ISSN: 1521-4095
Titre abrégé: Adv Mater
Pays: Germany
ID NLM: 9885358
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
18
06
2019
revised:
16
09
2019
pubmed:
7
11
2019
medline:
13
11
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Chirality is ubiquitous in nature and hard-wired into every biological system. Despite the prevalence of chirality in biological systems, controlling biomaterial chirality to influence interactions with cells has only recently been explored. Chiral-engineered supraparticles (SPs) that interact differentially with cells and proteins depending on their handedness are presented. SPs coordinated with d-chirality demonstrate greater than threefold enhanced cell membrane penetration in breast, cervical, and multiple myeloma cancer cells. Quartz crystal microbalance with dissipation and isothermal titration calorimetry measurements reveal the mechanism of these chiral-specific interactions. Thermodynamically, d-SPs show more stable adhesion to lipid layers composed of phospholipids and cholesterol compared to l-SPs. In vivo, d-SPs exhibit superior stability and longer biological half-lives likely due to opposite chirality and thus protection from endogenous proteins including proteases. This work shows that incorporating d-chirality into nanosystems enhances uptake by cancer cells and prolonged in vivo stability in circulation, providing support for the importance of chirality in biomaterials. Thus, chiral nanosystems may have the potential to provide a new level of control for drug delivery systems, tumor detection markers, biosensors, and other biomaterial-based devices.
Identifiants
pubmed: 31686433
doi: 10.1002/adma.201903878
pmc: PMC6986383
mid: NIHMS1058565
doi:
Substances chimiques
Biocompatible Materials
0
Lipid Bilayers
0
Lipids
0
Polyethylene Glycols
3WJQ0SDW1A
Cysteine
K848JZ4886
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1903878Subventions
Organisme : Koch Institute's Marble Center for Cancer Nanomedicine
Organisme : Fundação Estudar
Organisme : NIH HHS
ID : DP2 TR002776
Pays : United States
Organisme : NCATS NIH HHS
ID : DP2 TR002776
Pays : United States
Organisme : American Cancer Society
ID : 129784-IRG-16-188-38-IRG
Organisme : 2018 AACR-Bayer Innovation and Discovery
ID : 18-80-44-MITC
Organisme : Wellcome Fund Career
Organisme : National Research Foundation of Korea
ID : 2016M3A9B5942352
Organisme : NIH HHS
ID : F32EB022416
Pays : United States
Organisme : NIBIB NIH HHS
ID : F32 EB022416
Pays : United States
Organisme : CNPq
ID : 202856/2015-1
Informations de copyright
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Nat Rev Drug Discov. 2005 Jun;4(6):477-88
pubmed: 15931257
Biophys Chem. 2015 Aug-Sep;203-204:51-61
pubmed: 26042544
Drug Metab Rev. 2014 Aug;46(3):283-90
pubmed: 24796860
Nat Chem. 2018 Aug;10(8):821-830
pubmed: 30030537
Adv Mater. 2020 Oct;32(41):e1801790
pubmed: 30260543
Int J Biomed Sci. 2006 Jun;2(2):85-100
pubmed: 23674971
Trends Biochem Sci. 2009 Jun;34(6):296-302
pubmed: 19443222
J Am Chem Soc. 2012 Aug 8;134(31):13114-20
pubmed: 22793992
ACS Nano. 2015 Jul 28;9(7):6655-74
pubmed: 26149184
J Appl Toxicol. 2014 Apr;34(4):413-23
pubmed: 24243578
Nanomedicine. 2015 Aug;11(6):1407-16
pubmed: 25819884
Science. 2018 Jan 19;359(6373):309-314
pubmed: 29348234
Nat Nanotechnol. 2011 Aug 21;6(9):580-7
pubmed: 21857686
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4761-5
pubmed: 1693777
J Am Chem Soc. 2010 Mar 31;132(12):4038-9
pubmed: 20201523
J Nanobiotechnology. 2018 Jul 11;16(1):55
pubmed: 29996877
Chem Soc Rev. 2018 Feb 19;47(4):1516-1561
pubmed: 29362736
ACS Nano. 2018 Feb 27;12(2):954-964
pubmed: 29338193
Langmuir. 2011 Nov 15;27(22):13713-8
pubmed: 21958073
Nat Protoc. 2010 Jun;5(6):1096-106
pubmed: 20539285
Nat Rev Drug Discov. 2002 Oct;1(10):753-68
pubmed: 12360254
J Phys Chem B. 2011 Mar 31;115(12):2995-3002
pubmed: 21384939
ACS Biomater Sci Eng. 2018 Dec 10;4(12):4255-4265
pubmed: 31497639
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Nature. 2012 Jan 04;481(7381):348-51
pubmed: 22217941
Nano Lett. 2018 Oct 10;18(10):6279-6285
pubmed: 30216716
ACS Nano. 2019 Feb 26;13(2):2158-2166
pubmed: 30649859
Sci Adv. 2017 Mar 01;3(3):e1601159
pubmed: 28275728
Cancer Res. 2011 May 1;71(9):3236-45
pubmed: 21415164
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2474-2478
pubmed: 28228525
Nat Commun. 2014 May 20;5:3593
pubmed: 24845400
J Am Chem Soc. 2008 Jun 4;130(22):7077-84
pubmed: 18459786
Chem Rev. 2014 Jan 8;114(1):255-84
pubmed: 24050531
Nature. 2018 Apr;556(7701):360-365
pubmed: 29670265
Nat Commun. 2017 Feb 02;8:14312
pubmed: 28148957
Nat Mater. 2015 Jan;14(1):66-72
pubmed: 25401922
Nat Biotechnol. 2007 Oct;25(10):1165-70
pubmed: 17891134
Drugs. 1996;52 Suppl 5:1-12
pubmed: 8922553
Nat Rev Cancer. 2005 Jul;5(7):526-42
pubmed: 16069816
Nat Commun. 2018 Sep 25;9(1):3908
pubmed: 30254259